At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Pharmacological Study for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 64 participants across 188 sites in 3 countries.
Detailed Summary
This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
CountriesCanada, Saudi Arabia, United States
CollaboratorsRadiation Therapy Oncology Group, NRG Oncology
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartJan 2007
Primary CompletionMar 2011
Study CompletionSep 2018
TodayJul 2026
First PostedJan 18, 2007
Enrollment StartJan 24, 2007
Primary CompletionMar 9, 2011
Study CompletionSep 4, 2018
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 19.5 years ago
Interventions
Dasatinibdrug
Given PO
Pharmacological Studyother
Correlative studies